About

This information provides supporting context for the Vyepti (eptinezumab) Dosing Calculator. It outlines the key outputs, usage instructions, and clinical details relevant to the preparation and administration of Vyepti for the preventive treatment of migraine in adults. This content is for informational purposes and should not replace clinical judgment or the official Prescribing Information.

Outputs

The calculator provides a step-by-step summary for preparing and administering a selected dose of Vyepti. The key outputs include:

• Vials Required: The total number of 100 mg/mL single-dose vials needed.
• Volume to Withdraw: The specific volume (in mL) of eptinezumab to be drawn from the vial(s).
• Total Infusion Volume: The final volume after the drug is diluted in 100 mL of 0.9% Sodium Chloride.
• Infusion Rate: The calculated rate (in mL/hr) to administer the total volume over 30 minutes.

How to Use

To use the calculator, simply select the desired FDA-approved dose. The tool does not require patient weight as Vyepti is administered as a fixed dose.

• Select Required Dose: Choose either the 100 mg or 300 mg dose option.
• Calculate: The tool will automatically display the full preparation and administration instructions based on your selection.

Dosing Overview

Vyepti is administered via intravenous (IV) infusion every 3 months (quarterly). The recommended dosage is 100 mg. Some patients may benefit from a dosage of 300 mg. Both doses are diluted in 100 mL of 0.9% Sodium Chloride Injection, USP, and administered over approximately 30 minutes. No dose adjustments are required based on age, gender, race, or for patients with renal or hepatic impairment.

Switching

When switching a patient from another migraine preventive medication to Vyepti, the first dose of Vyepti can typically be administered on the day the next dose of the previous medication was scheduled. Clinicians should use their judgment based on the specific medication being discontinued and the patient’s clinical status.

Missed Dose

If a planned dose of Vyepti is missed, it should be administered as soon as possible. Subsequently, the dosing schedule should be adjusted to be every 3 months from the date of the last dose.

Safety Alerts

Vyepti is contraindicated in patients with serious hypersensitivity to eptinezumab or any of its excipients. Hypersensitivity reactions, including angioedema, urticaria, flushing, and rash, have been reported and can occur during or after the infusion. If a serious hypersensitivity reaction occurs, administration should be discontinued immediately and appropriate therapy initiated.

Frequently Asked Questions (FAQ)

• What are the approved doses for Vyepti? The FDA-approved doses are 100 mg and 300 mg, administered every 3 months.
• Why is patient weight not an input for the calculator? Vyepti dosing is fixed and not based on patient body weight.
• What is the concentration of Vyepti in each vial? Each single-dose vial contains 100 mg of eptinezumab in 1 mL of solution (100 mg/mL).
• How many vials are needed for a 300 mg dose? Three 100 mg/mL vials are required to prepare a 300 mg dose.
• What is the standard infusion time? The diluted solution is administered as a 30-minute intravenous infusion.
• What is the calculated infusion rate for a 100 mg dose? For a 100 mg dose (1 mL of drug) diluted in 100 mL, the total volume is 101 mL. Infused over 30 minutes (0.5 hours), the rate is 202 mL/hr.
• Can Vyepti be administered as an IV push or bolus? No, it must be diluted and administered as a 30-minute IV infusion.
• Can I use a different diluent besides 0.9% Sodium Chloride? No other diluents should be used. Refer to the full Prescribing Information for complete preparation details.
• How should the diluted solution be stored? If not used immediately, the diluted solution can be stored at room temperature (20°C to 25°C; 68°F to 77°F) for up to 8 hours. Do not freeze.
• Is this calculator a substitute for the official Prescribing Information? No, this tool is for educational support only and does not replace the full Prescribing Information, which should always be consulted.

References

• VYEPTI® (eptinezumab-jjmr) injection, for intravenous use. U.S. Prescribing Information. FDA.
• VYEPTI® (eptinezumab-jjmr) Official Healthcare Professional Site. Lundbeck.
• American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1-18.